Even in the absence of frank AAT deficiency, the AAT response to a systemic infection may be inadequate as has been shown for hospitalized COVID-19 patients [44,45] and among millions with certain heterozygous AAT mutations (PiMZ) [39]. This evidence concerns the gene SERPINA1 and COVID-19.